Form 4: Avanos Medical SVP Kerr Holbrook Reports Share Transactions
SEC Form 4
SVP, Chief Commercial Officer of Avanos Medical, Kerr Holbrook, reports acquisition and disposal of company stock related to restricted share units and tax obligations.
Summary
- Kerr Holbrook, SVP, Chief Commercial Officer of Avanos Medical, Inc., reported transactions involving Avanos Medical common stock on March 6, 2024.
- Holbrook acquired 36,573 shares of common stock at a price of $19.14 per share, representing time-based restricted share units (TRSUs) awarded under the company's 2021 Long Term Incentive Plan.
- These TRSUs vest in three equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
- Additionally, Holbrook disposed of 2,618 shares to satisfy tax withholding obligations upon the vesting of TRSUs awarded on March 6, 2023, with a portion vesting on March 6, 2024.
- Following these transactions, Holbrook beneficially owns 87,196 shares of Avanos Medical common stock.
- This total includes 149 shares acquired on December 31, 2023, and 782 shares acquired on June 30, 2023, under the Issuer's Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to stock-based compensation and tax obligations. There is no indication of unusual or concerning activity.
Positives
- The acquisition of 36,573 shares indicates a continued investment and alignment with the company's long-term performance.
Future Outlook
The reported transactions reflect the vesting schedule of previously granted restricted stock units and ongoing participation in the Employee Stock Purchase Plan, indicating continued long-term incentives for the reporting person.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation mechanisms.
Key Dates
| Date | Description |
|---|---|
| 2023-03-06 | Date of original TRSU award, 1/3 of which vested on March 6, 2024 |
| 2023-06-30 | Acquisition of 782 shares under the Employee Stock Purchase Plan |
| 2023-12-31 | Acquisition of 149 shares under the Employee Stock Purchase Plan |
| 2024-03-06 | Date of reported transactions: acquisition of 36,573 shares and disposal of 2,618 shares |
| 2025-03-06 | Vesting date for 1/3 of the TRSUs awarded on March 6, 2024 |
| 2026-03-06 | Vesting date for 1/3 of the TRSUs awarded on March 6, 2024 |
| 2027-03-06 | Vesting date for 1/3 of the TRSUs awarded on March 6, 2024 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.